more comprehensive therapy for patients with peripheral arterial disease (PAD)

February 2003

Experts now recommend more comprehensive therapy for patients with peripheral arterial disease (PAD).

In the past, treatment usually focused on relieving symptoms...most commonly claudication that limits walking.

But more emphasis is needed on slowing the underlying atherosclerosis...and reducing cardiovascular risk factors.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

New recommendations for testing C-reactive protein (CRP) will change the way you assess cardiovascular risk
potentially serious interaction between the RA drug Arava (leflunomide) and warfarin
Humira (Hu-MARE-ah, adalimumab), a new biologic therapy for rheumatoid arthritis
Fewer patients will be taking the antidepressant Serzone
There's a potential for errors with Depakote ER and Depakote
whether Serevent is safe
Singulair (montelukast) for treating seasonal allergic rhinitis
more comprehensive therapy for patients with peripheral arterial disease (PAD)
Substance Use Disorder two steroids being sold as dietary supplements
Substance Use Disorder all kinds of tricks to fool drug tests
Ophthalmology Xalatan is now approved for INITIAL treatment of glaucoma
Heart Failure Not enough heart failure patients get a beta-blocker
Infectious Diseases Alinia (nitazoxanide), a new antiprotozoal drug
Infectious Diseases whether the chickenpox vaccine (Varivax) is effective
Natural Medicines Should herbs and other supplements be stopped before surgery
Practice annual chart of new drugs approved in 2002